APA
Rosselli D., Rueda J. D., Wolowacz S., Brockbank J. & Abeysinghe S. (20160610). Cost-Effectiveness Of Dabigatran Compared With Warfarin, Apixaban, Rivaroxaban And Low Molecular Weight Heparins For The Treatment And Secondary Prevention Of Venous Thromboembolism In Colombia. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
Chicago
Rosselli D, Rueda J D, Wolowacz S, Brockbank J and Abeysinghe S. 20160610. Cost-Effectiveness Of Dabigatran Compared With Warfarin, Apixaban, Rivaroxaban And Low Molecular Weight Heparins For The Treatment And Secondary Prevention Of Venous Thromboembolism In Colombia. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
Harvard
Rosselli D., Rueda J. D., Wolowacz S., Brockbank J. and Abeysinghe S. (20160610). Cost-Effectiveness Of Dabigatran Compared With Warfarin, Apixaban, Rivaroxaban And Low Molecular Weight Heparins For The Treatment And Secondary Prevention Of Venous Thromboembolism In Colombia. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
MLA
Rosselli D, Rueda J D, Wolowacz S, Brockbank J and Abeysinghe S. Cost-Effectiveness Of Dabigatran Compared With Warfarin, Apixaban, Rivaroxaban And Low Molecular Weight Heparins For The Treatment And Secondary Prevention Of Venous Thromboembolism In Colombia. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20160610.